{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:51:47Z","timestamp":1791031907886,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s11064-014-1250-1","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T04:14:39Z","timestamp":1391400879000},"page":"1914-1923","source":"Crossref","is-referenced-by-count":87,"title":["Multi-target Design Strategies in the Context of Alzheimer\u2019s Disease: Acetylcholinesterase Inhibition and NMDA Receptor Antagonism as the Driving Forces"],"prefix":"10.1007","volume":"39","author":[{"given":"Michela","family":"Rosini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Minarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Melchiorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"1250_CR1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer\u2019s disease. Lancet 377:1019\u20131031","journal-title":"Lancet"},{"key":"1250_CR2","unstructured":"Alzheimer\u2019s Disease International, World Alzheimer Report. http:\/\/www.alz.co.uk\/research\/world-report-2012.WorldAlzheimerReport2012ExecutiveSummary.pdf"},{"key":"1250_CR3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrd2314","volume":"6","author":"I Melnikova","year":"2007","unstructured":"Melnikova I (2007) Therapies for Alzheimer\u2019s disease. Nat Rev Drug Discov 6:341\u2013342","journal-title":"Nat Rev Drug Discov"},{"key":"1250_CR4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2010","unstructured":"Citron M (2010) Alzheimer\u2019s disease: strategies for disease modification. Nat Rev Drug Discov 9:387\u2013398","journal-title":"Nat Rev Drug Discov"},{"key":"1250_CR5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","volume":"362","author":"HW Querfurth","year":"2010","unstructured":"Querfurth HW, LaFerla FM (2010) Alzheimer\u2019s disease. N Engl J Med 362:329\u2013344","journal-title":"N Engl J Med"},{"key":"1250_CR6","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","volume":"56","author":"JU Peters","year":"2013","unstructured":"Peters JU (2013) Polypharmacology\u2014foe or friend? J Med Chem 56:8955\u20138971","journal-title":"J Med Chem"},{"key":"1250_CR7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/13543776.18.4.387","volume":"18","author":"V Tumiatti","year":"2008","unstructured":"Tumiatti V, Bolognesi ML, Minarini A, Rosini M, Milelli A, Matera R, Melchiorre C (2008) Progress in acetylcholinesterase inhibitors for Alzheimer\u2019s disease: an update. Expert Opin Ther Patents 18:387\u2013401","journal-title":"Expert Opin Ther Patents"},{"key":"1250_CR8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jalz.2011.11.005","volume":"9","author":"S Gauthier","year":"2013","unstructured":"Gauthier S, Molinuevo JL (2013) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer\u2019s disease. Alzheimers Dement 9:326\u2013331","journal-title":"Alzheimers Dement"},{"key":"1250_CR9","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1177\/0091270006288734","volume":"46","author":"H Geerts","year":"2006","unstructured":"Geerts H, Grossberg GT (2006) Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer\u2019s disease. J Clin Pharmacol 46:8S\u201316S","journal-title":"J Clin Pharmacol"},{"key":"1250_CR10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","volume":"28","author":"L Patel","year":"2011","unstructured":"Patel L, Grossberg GT (2011) Combination therapy for Alzheimer\u2019s disease. Drugs Aging 28:539\u2013546","journal-title":"Drugs Aging"},{"key":"1250_CR11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"CG Parsons","year":"2013","unstructured":"Parsons CG, Danysz W, Dekundy A, Pulte I (2013) Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer\u2019s disease. Neurotox Res 24:358\u2013369","journal-title":"Neurotox Res"},{"key":"1250_CR12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0197-4580(89)90143-7","volume":"10","author":"JT Greenamyre","year":"1989","unstructured":"Greenamyre JT, Young AB (1989) Excitatory amino acids and Alzheimer\u2019s disease. Neurobiol Aging 10:593\u2013602","journal-title":"Neurobiol Aging"},{"key":"1250_CR13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0006-8993(94)91590-3","volume":"655","author":"GL Wenk","year":"1994","unstructured":"Wenk GL, Danysz W, Mobley SL (1994) Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res 655:7\u201311","journal-title":"Brain Res"},{"key":"1250_CR14","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1523\/JNEUROSCI.3979-05.2006","volume":"26","author":"TG Allen","year":"2006","unstructured":"Allen TG, Abogadie FC, Brown DA (2006) Simultaneous release of glutamate and acetylcholine from single magnocellular \u201ccholinergic\u201d basal forebrain neurons. J Neurosci 26:1588\u20131595","journal-title":"J Neurosci"},{"key":"1250_CR15","unstructured":"http:\/\/www.adamaspharma.com\/PR20121505.aspx"},{"key":"1250_CR16","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","volume":"48","author":"R Morphy","year":"2005","unstructured":"Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48:6523\u20136543","journal-title":"J Med Chem"},{"key":"1250_CR17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","volume":"51","author":"A Cavalli","year":"2008","unstructured":"Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347\u2013372","journal-title":"J Med Chem"},{"key":"1250_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cbpa.2009.04.619","volume":"13","author":"ML Bolognesi","year":"2009","unstructured":"Bolognesi ML, Matera R, Minarini A, Rosini M, Melchiorre C (2009) Alzheimer\u2019s disease: new approaches to drug discovery. Curr Opin Chem Biol 13:303\u2013308","journal-title":"Curr Opin Chem Biol"},{"key":"1250_CR19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.drudis.2006.12.006","volume":"12","author":"R Morphy","year":"2007","unstructured":"Morphy R, Rankovic Z (2007) Fragments, network biology and designing multiple ligands. Drug Discov Today 12:156\u2013160","journal-title":"Drug Discov Today"},{"key":"1250_CR20","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2174\/156802611798184373","volume":"11","author":"ML Bolognesi","year":"2011","unstructured":"Bolognesi ML, Simoni E, Rosini M, Minarini A, Tumiatti V, Melchiorre C (2011) Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer\u2019s disease. Curr Top Med Chem 11:2797\u20132806","journal-title":"Curr Top Med Chem"},{"key":"1250_CR21","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","volume":"20","author":"ML Bolognesi","year":"2013","unstructured":"Bolognesi ML (2013) Polypharmacology in a single drug: multitarget drugs. Curr Med Chem 20:1639\u20131645","journal-title":"Curr Med Chem"},{"key":"1250_CR22","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2174\/15680266113139990136","volume":"13","author":"A Minarini","year":"2013","unstructured":"Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V (2013) Multifunctional tacrine derivatives in Alzheimer\u2019s disease. Curr Top Med Chem 13:1771\u20131786","journal-title":"Curr Top Med Chem"},{"key":"1250_CR23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/med.20248","volume":"33","author":"R Leon","year":"2013","unstructured":"Leon R, Garcia AG, Marco-Contelles J (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer\u2019s disease. Med Res Rev 33:139\u2013189","journal-title":"Med Res Rev"},{"key":"1250_CR24","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1021\/jm9810452","volume":"41","author":"C Melchiorre","year":"1998","unstructured":"Melchiorre C, Andrisano V, Bolognesi ML, Budriesi R, Cavalli A, Cavrini V, Rosini M, Tumiatti V, Recanatini M (1998) Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer\u2019s disease. J Med Chem 41:4186\u20134189","journal-title":"J Med Chem"},{"key":"1250_CR25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"RT Bartus","year":"1982","unstructured":"Bartus RT, Dean RL 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408\u2013414","journal-title":"Science"},{"key":"1250_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/exnr.2000.7397","volume":"163","author":"RT Bartus","year":"2000","unstructured":"Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495\u2013529","journal-title":"Exp Neurol"},{"key":"1250_CR27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1126\/science.1132813","volume":"314","author":"ED Roberson","year":"2006","unstructured":"Roberson ED, Mucke L (2006) 100\u00a0years and counting: prospects for defeating Alzheimer\u2019s disease. Science 314:781\u2013784","journal-title":"Science"},{"key":"1250_CR28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.coph.2005.01.014","volume":"5","author":"I Silman","year":"2005","unstructured":"Silman I, Sussman JL (2005) Acetylcholinesterase: \u2018classical\u2019 and \u2018non-classical\u2019 functions and pharmacology. Curr Opin Pharmacol 5:293\u2013302","journal-title":"Curr Opin Pharmacol"},{"key":"1250_CR29","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2174\/138955708785740652","volume":"8","author":"ML Bolognesi","year":"2008","unstructured":"Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Melchiorre C (2008) From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer\u2019s disease. Mini-Rev Med Chem 8:960\u2013967","journal-title":"Mini-Rev Med Chem"},{"key":"1250_CR30","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2174\/092986708785909067","volume":"15","author":"D Munoz-Torrero","year":"2008","unstructured":"Munoz-Torrero D (2008) Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer\u2019s disease. Curr Med Chem 15:2433\u20132455","journal-title":"Curr Med Chem"},{"key":"1250_CR31","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.2174\/138161206778792985","volume":"12","author":"A Castro","year":"2006","unstructured":"Castro A, Martinez A (2006) Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 12:4377\u20134387","journal-title":"Curr Pharm Des"},{"key":"1250_CR32","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.2174\/15680266113139990139","volume":"13","author":"E Viayna","year":"2013","unstructured":"Viayna E, Sabate R, Munoz-Torrero D (2013) Dual inhibitors of beta-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. Curr Top Med Chem 13:1820\u20131842","journal-title":"Curr Top Med Chem"},{"key":"1250_CR33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1476-5381.2012.02057.x","volume":"167","author":"W Danysz","year":"2012","unstructured":"Danysz W, Parsons CG (2012) Alzheimer\u2019s disease, beta-amyloid, glutamate, NMDA receptors and memantine\u2014searching for the connections. Br J Pharmacol 167:324\u2013352","journal-title":"Br J Pharmacol"},{"key":"1250_CR34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrd1958","volume":"5","author":"SA Lipton","year":"2006","unstructured":"Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160\u2013170","journal-title":"Nat Rev Drug Discov"},{"key":"1250_CR35","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bbr.2010.05.033","volume":"221","author":"C Nyakas","year":"2011","unstructured":"Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG (2011) The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-beta42 with memantine. Behav Brain Res 221:594\u2013603","journal-title":"Behav Brain Res"},{"key":"1250_CR36","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0006-2952(98)00275-5","volume":"56","author":"PG Lysko","year":"1998","unstructured":"Lysko PG, Lysko KA, Webb CL, Feuerstein G, Mason PE, Walter MF, Mason RP (1998) Neuroprotective activities of carvedilol and a hydroxylated derivative: role of membrane biophysical interactions. Biochem Pharmacol 56:1645\u20131656","journal-title":"Biochem Pharmacol"},{"issue":"Pt 2","key":"1250_CR37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1042\/0264-6021:3430419","volume":"343","author":"DR Howlett","year":"1999","unstructured":"Howlett DR, George AR, Owen DE, Ward RV, Markwell RE (1999) Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem J 343(Pt 2):419\u2013423","journal-title":"Biochem J"},{"key":"1250_CR38","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1021\/jm800577j","volume":"51","author":"M Rosini","year":"2008","unstructured":"Rosini M, Simoni E, Bartolini M, Cavalli A, Ceccarini L, Pascu N, McClymont DW, Tarozzi A, Bolognesi ML, Minarini A, Tumiatti V, Andrisano V, Mellor IR, Melchiorre C (2008) Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer\u2019s disease: a promising direction for the multi-target-directed ligands gold rush. J Med Chem 51:4381\u20134384","journal-title":"J Med Chem"},{"key":"1250_CR39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/jm049112h","volume":"48","author":"M Rosini","year":"2005","unstructured":"Rosini M, Andrisano V, Bartolini M, Bolognesi ML, Hrelia P, Minarini A, Tarozzi A, Melchiorre C (2005) Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem 48:360\u2013363","journal-title":"J Med Chem"},{"key":"1250_CR40","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1016\/j.ejmech.2011.09.001","volume":"46","author":"M Rosini","year":"2011","unstructured":"Rosini M, Simoni E, Bartolini M, Tarozzi A, Matera R, Milelli A, Hrelia P, Andrisano V, Bolognesi ML, Melchiorre C (2011) Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer\u2019s disease. Eur J Med Chem 46:5435\u20135442","journal-title":"Eur J Med Chem"},{"key":"1250_CR41","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2174\/092986710791111206","volume":"17","author":"V Tumiatti","year":"2010","unstructured":"Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C (2010) Tacrine derivatives and Alzheimer\u2019s disease. Curr Med Chem 17:1825\u20131838","journal-title":"Curr Med Chem"},{"key":"1250_CR42","doi-asserted-by":"crossref","first-page":"e31921","DOI":"10.1371\/journal.pone.0031921","volume":"7","author":"R Pi","year":"2012","unstructured":"Pi R, Mao X, Chao X, Cheng Z, Liu M, Duan X, Ye M, Chen X, Mei Z, Liu P, Li W, Han Y (2012) Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-beta-mediated Alzheimer\u2019s disease-associated pathogenesis in vitro and in vivo. PLoS One 7:e31921","journal-title":"PLoS One"},{"key":"1250_CR43","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/cns.12010","volume":"18","author":"WY Huang","year":"2012","unstructured":"Huang WY, Chao XJ, Ouyang Y, Liu AM, He XX, Chen MH, Wang LH, Liu J, Yu SW, Rapposelli S, Pi RB (2012) Tacrine-6-ferulic acid, a novel multifunctional dimer against Alzheimer\u2019s disease, prevents oxidative stress-induced neuronal death through activating Nrf2\/ARE\/HO-1 pathway in HT22 cells. CNS Neurosci Ther 18:950\u2013951","journal-title":"CNS Neurosci Ther"},{"key":"1250_CR44","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuint.2011.09.001","volume":"59","author":"H Zhang","year":"2011","unstructured":"Zhang H, Mak S, Cui W, Li W, Han R, Hu S, Ye M, Pi R, Han Y (2011) Tacrine(2)-ferulic acid, a novel multifunctional dimer, attenuates 6-hydroxydopamine-induced apoptosis in PC12 cells by activating Akt pathway. Neurochem Int 59:981\u2013988","journal-title":"Neurochem Int"},{"key":"1250_CR45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","volume":"53","author":"CG Parsons","year":"2007","unstructured":"Parsons CG, Stoffler A, Danysz W (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2014too little activation is bad, too much is even worse. Neuropharmacology 53:699\u2013723","journal-title":"Neuropharmacology"},{"key":"1250_CR46","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.1177\/0091270006288735","volume":"46","author":"GT Grossberg","year":"2006","unstructured":"Grossberg GT, Edwards KR, Zhao Q (2006) Rationale for combination therapy with galantamine and memantine in Alzheimer\u2019s disease. J Clin Pharmacol 46:17S\u201326S","journal-title":"J Clin Pharmacol"},{"key":"1250_CR47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1254\/jphs.12166SC","volume":"120","author":"P Busquet","year":"2012","unstructured":"Busquet P, Capurro V, Cavalli A, Piomelli D, Reggiani A, Bertorelli R (2012) Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice. J Pharmacol Sci 120:305\u2013309","journal-title":"J Pharmacol Sci"},{"key":"1250_CR48","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","volume":"305","author":"M Samochocki","year":"2003","unstructured":"Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, Maelicke A (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024\u20131036","journal-title":"J Pharmacol Exp Ther"},{"key":"1250_CR49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2006.08.017","volume":"549","author":"Y Takada-Takatori","year":"2006","unstructured":"Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Niidome T, Sugimoto H, Fujii T, Okabe S, Akaike A (2006) Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. Eur J Pharmacol 549:19\u201326","journal-title":"Eur J Pharmacol"},{"key":"1250_CR50","doi-asserted-by":"crossref","first-page":"9708","DOI":"10.1021\/jm3009458","volume":"55","author":"E Simoni","year":"2012","unstructured":"Simoni E, Daniele S, Bottegoni G, Pizzirani D, Trincavelli ML, Goldoni L, Tarozzo G, Reggiani A, Martini C, Piomelli D, Melchiorre C, Rosini M, Cavalli A (2012) Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer\u2019s disease. J Med Chem 55:9708\u20139721","journal-title":"J Med Chem"},{"key":"1250_CR51","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s11064-012-0726-0","volume":"37","author":"Z Liu","year":"2012","unstructured":"Liu Z, Lv C, Zhao W, Song Y, Pei D, Xu T (2012) NR2B-containing NMDA receptors expression and their relationship to apoptosis in hippocampus of Alzheimer\u2019s disease-like rats. Neurochem Res 37:1420\u20131427","journal-title":"Neurochem Res"},{"key":"1250_CR52","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1476-5381.2009.00304.x","volume":"157","author":"L Mony","year":"2009","unstructured":"Mony L, Kew JN, Gunthorpe MJ, Paoletti P (2009) Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 157:1301\u20131317","journal-title":"Br J Pharmacol"},{"key":"1250_CR53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2174\/0929867043456061","volume":"11","author":"PL Chazot","year":"2004","unstructured":"Chazot PL (2004) The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr Med Chem 11:389\u2013396","journal-title":"Curr Med Chem"},{"key":"1250_CR54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/brb3.118","volume":"3","author":"JP Lopes","year":"2013","unstructured":"Lopes JP, Tarozzo G, Reggiani A, Piomelli D, Cavalli A (2013) Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain Behav 3:67\u201374","journal-title":"Brain Behav"},{"key":"1250_CR55","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuropharm.2006.04.007","volume":"51","author":"Y Takada-Takatori","year":"2006","unstructured":"Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A (2006) Acetylcholinesterase inhibitors used in treatment of Alzheimer\u2019s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51:474\u2013486","journal-title":"Neuropharmacology"},{"key":"1250_CR56","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(08)61046-6","volume":"372","author":"A Burns","year":"2008","unstructured":"Burns A, Jacoby R (2008) Dimebon in Alzheimer\u2019s disease: old drug for new indication. Lancet 372:179\u2013180","journal-title":"Lancet"},{"key":"1250_CR57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","volume":"372","author":"RS Doody","year":"2008","unstructured":"Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled study. Lancet 372:207\u2013215","journal-title":"Lancet"},{"key":"1250_CR58","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1749-6632.2001.tb03654.x","volume":"939","author":"S Bachurin","year":"2001","unstructured":"Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N (2001) Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 939:425\u2013435","journal-title":"Ann NY Acad Sci"},{"key":"1250_CR59","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.327.5971.1309","volume":"327","author":"G Miller","year":"2010","unstructured":"Miller G (2010) Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer\u2019s drug. Science 327:1309","journal-title":"Science"},{"key":"1250_CR60","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1021\/jm010158+","volume":"44","author":"PS Portoghese","year":"2001","unstructured":"Portoghese PS (2001) From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J Med Chem 44:2259\u20132269","journal-title":"J Med Chem"},{"key":"1250_CR61","doi-asserted-by":"crossref","first-page":"23646","DOI":"10.1074\/jbc.271.39.23646","volume":"271","author":"YP Pang","year":"1996","unstructured":"Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S (1996) Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer\u2019s disease. J Biol Chem 271:23646\u201323649","journal-title":"J Biol Chem"},{"key":"1250_CR62","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1002\/anie.200700256","volume":"46","author":"A Cavalli","year":"2007","unstructured":"Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, Margotti E, Cattaneo A, Recanatini M, Melchiorre C (2007) A small molecule targeting the multifactorial nature of Alzheimer\u2019s disease. Angew Chem Int Ed Engl 46:3689\u20133692","journal-title":"Angew Chem Int Ed Engl"},{"key":"1250_CR63","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.neuropharm.2011.10.007","volume":"62","author":"A Minarini","year":"2012","unstructured":"Minarini A, Milelli A, Tumiatti V, Rosini M, Simoni E, Bolognesi ML, Andrisano V, Bartolini M, Motori E, Angeloni C, Hrelia S (2012) Cystamine\u2013tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer\u2019s disease treatment. Neuropharmacology 62:997\u20131003","journal-title":"Neuropharmacology"},{"key":"1250_CR64","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1021\/jm200691d","volume":"54","author":"ML Bolognesi","year":"2011","unstructured":"Bolognesi ML, Chiriano G, Bartolini M, Mancini F, Bottegoni G, Maestri V, Czvitkovich S, Windisch M, Cavalli A, Minarini A, Rosini M, Tumiatti V, Andrisano V, Melchiorre C (2011) Synthesis of monomeric derivatives to probe memoquin\u2019s bivalent interactions. J Med Chem 54:8299\u20138304","journal-title":"J Med Chem"},{"key":"1250_CR65","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/cmdc.201000086","volume":"5","author":"ML Bolognesi","year":"2010","unstructured":"Bolognesi ML, Bartolini M, Mancini F, Chiriano G, Ceccarini L, Rosini M, Milelli A, Tumiatti V, Andrisano V, Melchiorre C (2010) Bis(7)-tacrine derivatives as multitarget-directed ligands: focus on anticholinesterase and antiamyloid activities. ChemMedChem 5:1215\u20131220","journal-title":"ChemMedChem"},{"key":"1250_CR66","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1021\/jm8009684","volume":"51","author":"V Tumiatti","year":"2008","unstructured":"Tumiatti V, Milelli A, Minarini A, Rosini M, Bolognesi ML, Micco M, Andrisano V, Bartolini M, Mancini F, Recanatini M, Cavalli A, Melchiorre C (2008) Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. J Med Chem 51:7308\u20137312","journal-title":"J Med Chem"},{"key":"1250_CR67","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1021\/jm0494366","volume":"47","author":"V Tumiatti","year":"2004","unstructured":"Tumiatti V, Andrisano V, Banzi R, Bartolini M, Minarini A, Rosini M, Melchiorre C (2004) Structure\u2013activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties. J Med Chem 47:6490\u20136498","journal-title":"J Med Chem"},{"key":"1250_CR68","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1021\/jm021055+","volume":"46","author":"V Tumiatti","year":"2003","unstructured":"Tumiatti V, Rosini M, Bartolini M, Cavalli A, Marucci G, Andrisano V, Angeli P, Banzi R, Minarini A, Recanatini M, Melchiorre C (2003) Structure\u2013activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. J Med Chem 46:954\u2013966","journal-title":"J Med Chem"},{"key":"1250_CR69","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/jm049510k","volume":"48","author":"G Campiani","year":"2005","unstructured":"Campiani G, Fattorusso C, Butini S, Gaeta A, Agnusdei M, Gemma S, Persico M, Catalanotti B, Savini L, Nacci V, Novellino E, Holloway HW, Greig NH, Belinskaya T, Fedorko JM, Saxena A (2005) Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. J Med Chem 48:1919\u20131929","journal-title":"J Med Chem"},{"key":"1250_CR70","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1747-0285.2011.01110.x","volume":"77","author":"AA Reinke","year":"2011","unstructured":"Reinke AA, Gestwicki JE (2011) Insight into amyloid structure using chemical probes. Chem Biol Drug Des 77:399\u2013411","journal-title":"Chem Biol Drug Des"},{"key":"1250_CR71","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/cmdc.201300263","volume":"8","author":"M Rosini","year":"2013","unstructured":"Rosini M, Simoni E, Bartolini M, Soriano E, Marco-Contelles J, Andrisano V, Monti B, Windisch M, Hutter-Paier B, McClymont DW, Mellor IR, Bolognesi ML (2013) The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. ChemMedChem 8:1276\u20131281","journal-title":"ChemMedChem"},{"key":"1250_CR72","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/cbic.200900666","volume":"11","author":"M Bartolini","year":"2010","unstructured":"Bartolini M, Andrisano V (2010) Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem 11:1018\u20131035","journal-title":"ChemBioChem"},{"key":"1250_CR73","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s007020170067","volume":"108","author":"M Hartbauer","year":"2001","unstructured":"Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M (2001) Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm 108:459\u2013473","journal-title":"J Neural Transm"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-014-1250-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-014-1250-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-014-1250-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:34:58Z","timestamp":1559349298000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-014-1250-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s11064-014-1250-1","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]}}}